Distress to Success is written for the business leader struggling to return a company from the “red” into the “black.” It is written for the savvy buyer straining to find acquisition opportunities in an unrealistic market. If you are one of these two kinds of people, it is written for you.
Jeff Hayzlett is a big, boisterous guy who has the guts to get in your face and tell you exactly why your business isn’t doing well. In short, he asks the questions that most business managers are afraid to ask. And as Jeff points out, if you aren’t willing to look at what’s working and what isn’t – and then take thenecessary steps to fix them — well, you and your colleagues and employees are in for a tough ride.
May 13, 2010: by Bobby Guy, Jennifer O’Guinn, (TMA International Headquarters)
Reorganization is a tough business when capital is inaccessible. It’s no secret that true Chapter 11 reorganizations are few and far between; the Chapter 11 bankruptcy process is now used frequently as a sales mechanism through its very powerful Section 363 sale process. The market demands sales, and to attract the highest prices, it demands the certainty of a Section 363 sale. Indeed, from the perspective of the market, Chapter 11 may be the most efficient liquidation mechanism in the world. Read More
May 14, 2009: by Ryan K. Cochran, Bobby Guy, Katie Grainer Stenberg
(TMA International Headquarters) A Bankruptcy Code Section 363 sale is often the exit strategy of choice for distressed companies and their suitors. There are a number of reasons for this, one of the most important being the ability to get a Bankruptcy Court to issue an order blessing the sale and protecting the buyer from prickly liabilities. With Chapter 11 filings now predicted to hit historic highs and Wall Street’s remaining liquidity sources lost in a sea of confusion, the prevalence of 363 sales is likely to increase dramatically.
By Daniel Brettler, Senior Vice President, Life Science & Technology Practice Leader, Conner Strong
Our country is facing one of the worst financial crises in more than a generation. Life science and technology companies face many of the same struggles seen throughout the country. Inability to raise capital, increased operating costs, increased global competition and increased governmental and industry regulations are just a few.